tll-018
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05133297)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06887127 | Phase 3 | Mar 10, 2025 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT06396026 | Phase 3 | May 30, 2024 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT06020144 | Phase 3 | Nov 15, 2023 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT05945810 | Phase 1 | Jul 12, 2023 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| NCT05133297 | Phase 2 | Dec 31, 2021 | Hangzhou Highlightll Pharmaceutical Co., Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hangzhou Highlightll Pharmaceutical Co., Ltd | For profit | 5 | 5 | 3 | 2021 |
1 organizations
Page 1 / 1